Prevention of skeletal muscle and myocardial free-fatty acid induced microvascular dysfunction in skeletal muscle and myocardium by exercise

Prevention of skeletal muscle and myocardial free-fatty acid induced microvascular dysfunction in skeletal muscle and myocardium by exercise - Prevention of microvascular dysfunction by exercise

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43964

Enrollment

Registered

2015-07-16

Start date

2015-08-06

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ill bloodvessels microvascular dysfunction

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Young healthy male subjects. Age 18-30 years.

Exclusion criteria

Exclusion criteria: A drastic recent change in physical activity (eg. just stopped being an athlete), conditions that can significantly influence the amount of energy that is needed for physical activity (eg. a lower-leg prothesis), history of obesity, hypertension, diabetes mellitus, hyperlipidemia, smoking (currently, or > 1 package per month over the last 2 years), documented cardiovascular disease, use of medication that could potentially affect insulin sensitivity or microvascular function or inflammatory status.

Design outcomes

Primary

Measure	Time frame
The effect of FFA on insulin-induced changes in microvascular blood volume of skeletal muscle and myocardium will be correlated with amount of physical activity as measured with accelerometers and VO2max.	—

Secondary

Measure	Time frame
Secundary endpoints will be microvascular blood volume during basal and hyperinsulinemic state without Intralipid infusion, in myocardium and skeletal muscle. Also, whole-body insulin sensitivity as measured by the glucose infusion rate will be correlated with physical activity. Body fat percentage and blood pressure (Nexfin) will be measured to test if these parameters are equal between subjects and if not in which amount they differ. Contraction induced microvascular recruitment will be measured with the handgrip dynamometer to test if we can show an increase of MBV with Ceus during a different physiological parameter than insulin alone.	—

Measure

Time frame

Secundary endpoints will be microvascular blood volume during basal and hyperinsulinemic state without Intralipid infusion, in myocardium and skeletal muscle. Also, whole-body insulin sensitivity as measured by the glucose infusion rate will be correlated with physical activity. Body fat percentage and blood pressure (Nexfin) will be measured to test if these parameters are equal between subjects and if not in which amount they differ. Contraction induced microvascular recruitment will be measured with the handgrip dynamometer to test if we can show an increase of MBV with Ceus during a different physiological parameter than insulin alone.

—

Countries

Netherlands

Outcome results